Modification by ALAD of the association between blood lead and blood pressure in the U.S. population: Results from the Third National Health and Nutrition Examination Survey

Environmental Health Perspectives

Volumn 118, Issue 2, 2010, Pages 259-264

  Scinicariello, Franco ^a   Yesupriya, Ajay ^b   Chang, Man Huei ^b   Fowler, Bruce A ^a  

^a AGENCY FOR TOXIC SUBSTANCES AND DISEASE REGISTRY   (United States)

^b NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

ALAD polymorphism; Blood pressure; Hypertension; Lead; NHANES

Indexed keywords

DNA; LEAD; PORPHOBILINOGEN SYNTHASE;

ADULT; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ETHNIC DIFFERENCE; EXPOSURE; FEMALE; GENE FUNCTION; GENOTYPE; HEALTH SURVEY; HOMOZYGOSITY; HUMAN; HYPERTENSION; LEAD BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; RACE DIFFERENCE; SYSTOLIC BLOOD PRESSURE; UNITED STATES;

ADOLESCENT; ADULT; BLOOD PRESSURE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEAD; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PORPHOBILINOGEN SYNTHASE; YOUNG ADULT;

EID: 77149151859     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.0900866     Document Type: Article

References (45)

1. Agency for Toxic Substances and Disease Registry. 1999. Toxicological Profile for Cadmium. Atlanta, GA: Agency for Toxic Substances and Disease Registry.
2. Barbosa F Jr, Sertorio JT, Gerlach RF, Tanus-Santos JE. 2006. Clinical evidence for lead-induced inhibition of nitric oxide formation. Arch Toxicol 80:811-816.
3. Battistuzzi G, Petrucci R, Silvagni L, Urbani FR, Caiola S. 1981. delta-Aminolevulinate dehydrase: a new genetic polymorphism in man. Ann Hum Genet 45:223-229.
4. Bergdahl IA, Grubb A, Schutz A, Desnick RJ, Wetmur JG, Sassa S, et al. 1997. Lead binding to delta-aminolevulinic acid dehydratase (ALAD) in human erythrocytes. Pharmacol Toxicol 81:153-158.
5. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, et al. 1995. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 25:305-313.
6. CDC. 1991. National Health and Nutrition Examination Survey III Cycle 2. Blood Pressure Quality Control Program. Atlanta, GA:Centers for Disease Control and Prevention, National Center for Environmental Health. Available: http://www.cdc.gov/nchs/data/nhanes/nhanes3/cdrom/nchs/manuals/bpqc.pdf [accessed 27 February 2009].
7. CDC. 2002. Managing Elevated BLLs among Young Children. Atlanta, GA:Centers for Disease Control and Prevention, National Center for Environmental Health.
8. Chang MH, Lindegren ML, Butler MA, Chanock SJ, Dowling NF, Gallagher M, et al. 2009. Prevalence in the United States of selected candidate gene variants: Third National Health and Nutrition Examination Survey, 1991-1994. Am J Epidemiol 169:54-66.
9. Chowdhary S, Townend JN. 2001. Nitric oxide and hypertension: not just an endothelium derived relaxing factor! J Hum Hypertens 15:219-227.
10. Den Hond E, Nawrot T, Staessen JA. 2002. The relationship between blood pressure and blood lead in NHANES III. National Health and Nutritional Examination Survey. J Hum Hypertens 16:563-568.
11. Gunter EW, Lewis BG, Koncikowski SM. 1996. Laboratory Procedures Used for the Third National Health and Nutrition Examination Survey (NHANES III), 1988-1994. Available: http://www.cdc.gov/nchs/data/nhanes/nhanes3/cdrom/nchs/ manuals/labman.pdf [accessed 27 February 2009].
12. Gwiazda R, Campbell C, Smith D. 2005. A noninvasive isotopic approach to estimate the bone lead contribution to blood in children: implications for assessing the efficacy of lead abatement. Environ Health Perspect 113:104-110.
13. Hense HW, Filipiak B, Keil U. 1993. The association of blood lead and blood pressure in population surveys. Epidemiology 4:173-179.
14. Hense HW, Filipiak B, Keil U. 1994. Alcohol consumption as a modifier of the relation between blood lead and blood pressure. Epidemiology 5:120-123.
15. Hu H, Aro A, Payton M, Korrick S, Sparrow D, Weiss ST, et al. 1996. The relationship of bone and blood lead to hypertension. The Normative Aging Study. JAMA 275:1171-1176.
16. Kelada SN, Shelton E, Kaufmann RB, Khoury MJ. 2001. Delta-aminolevulinic acid dehydratase genotype and lead toxicity: a HuGE review. Am J Epidemiol 154:1-13.
17. Kosnett MJ, Wedeen RP, Rothenberg SJ, Hipkins KL, Materna BL, Schwartz BS, et al. 2007. Recommendations for medical management of adult lead exposure. Environ Health Perspect 115:463-471.
18. Lee BK, Lee GS, Stewart WF, Ahn KD, Simon D, Kelsey KT, et al. 2001. Associations of blood pressure and hypertension with lead dose measures and polymorphisms in the vitamin D receptor and delta-aminolevulinic acid dehydratase genes. Environ Health Perspect 109:383-389.
19. Lohr SL. 1999. Sampling: Design and Analysis. Pacific Grove, CA:Duxbury Press.
20. Montenegro MF, Barbosa F Jr, Sandrim VC, Gerlach RF, Tanus-Santos JE. 2006. A polymorphism in the delta-aminolevulinic acid dehydratase gene modifies plasma/whole blood lead ratio. Arch Toxicol.80:394-398.
21. Muntner P, He J, Vupputuri S, Coresh J, Batuman V. 2003. Blood lead and chronic kidney disease in the general United States population: results from NHANES III. Kidney Int 63:1044-1050.
22. Muntner P, Menke A, DeSalvo KB, Rabito FA, Batuman V. 2005. Continued decline in blood lead levels among adults in the United States: the National Health and Nutrition Examination Surveys. Arch Intern Med 165:2155-2161.
23. Nash D, Magder L, Lustberg M, Sherwin RW, Rubin RJ, Kaufmann RB, et al. 2003. Blood lead, blood pressure, and hypertension in perimenopausal and postmenopausal women. JAMA 289:1523-1532.
24. National Center for Health Statistics. 1994. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-94. Series 1: programs and collection procedures. Vital Health Stat 32:1-407.
25. Navas-Acien A, Guallar E, Silbergeld EK, Rothenberg SJ. 2007. Lead exposure and cardiovascular disease-a systematic review. Environ Health Perspect 115:472-482.
26. Navas-Acien A, Selvin E, Sharrett AR, Calderon-Aranda E, Silbergeld E, Guallar E. 2004. Lead, cadmium, smoking, and increased risk of peripheral arterial disease. Circulation 109:3196-3201.
27. Nawrot TS, Thijs L, Den Hond EM, Roels HA, Staessen JA. 2002. An epidemiological re-appraisal of the association between blood pressure and blood lead: a meta-analysis. J Hum Hypertens 16:123-131
28. Nordberg M, Winblad B, Fratiglioni L, Basun H. 2000. Lead concentrations in elderly urban people related to blood pressure and mental performance: results from a population-based study. Am J Ind Med 38:290-294.
29. O'Rourke MF, Mancia G. 1999. Arterial stiffness. J Hypertens 17:1-4.
30. Perlstein T, Weuve J, Schwartz J, Sparrow D, Wright R, Litonjua A, et al. 2007. Cumulative community-level lead exposure and pulse pressure: the normative aging study. Environ Health Perspect 115:1696-1700.
31. Pirkle JL, Brody DJ, Gunter EW, Kramer RA, Paschal DC, Flegal KM, et al. 1994. The decline in blood lead levels in the United States. The National Health and Nutrition Examination Surveys (NHANES). JAMA 272:284-291.
32. Pirkle JL, Schwartz J, Landis JR, Harlan WR. 1985. The relationship between blood lead levels and blood pressure and its cardiovascular risk implications. Am J Epidemiol 121:246-258.
33. Poklis A. 1975. The lead content of the aorta in male residents of Baltimore, Maryland. Bull Environ Contam Toxicol 13:417-419.
34. Schroeder HA, Tipton IH. 1968. The human body burden of lead. Arch Environ Health 17:965-978.
35. Schwartz BS, Hu H. 2007. Adult lead exposure: time for change. Environ Health Perspect 115:451-454.
36. Schwartz BS, Lee BK, Stewart W, Ahn KD, Springer K, Kelsey K. 1995. Associations of delta-aminolevulinic acid dehydratase genotype with plant, exposure duration, and blood lead and zinc protoporphyrin levels in Korean lead workers. Am J Epidemiol 142:738-745.
37. Schwartz J. 1991. Lead, blood pressure and cardiovascular disease in men and women. Environ Health Perspect 91:71-75.
38. Scinicariello F, Murray HE, Moffett DB, Abadin HG, Sexton MJ, Fowler BA. 2007. Lead and delta-aminolevulinic acid dehydratase polymorphism: where does it lead? A meta-analysis. Environ Health Perspect 115:35-41.
39. Smith CM, Wang X, Hu H, Kelsey KT. 1995. A polymorphism in the delta-aminolevulinic acid dehydratase gene may modify the pharmacokinetics and toxicity of lead. Environ Health Perspect 103:248-253.
40. Telisman S, Jurasović J, Pizent A, Cvitković P. 2001. Blood pressure in relation to biomarkers of lead, cadmium, copper, zinc, and selenium in men without occupational exposure to metals. Environ Res 87:57-68.
41. Todd AC, Lee BK, Lee GS, Ahn KD, Moshier EL, Schwartz BS. 2001. Predictors of DMSA chelatable lead, tibial lead, and blood lead in 802 Korean lead workers. Occup Environ Med 58:73-80.
42. Vaziri ND, Ding Y. 2001. Effect of lead on nitric oxide synthase expression in coronary endothelial cells: role of superoxide. Hypertension 37:223-226.
43. Vaziri ND, Liang K, Ding Y. 1999. Increased nitric oxide inactivation by reactive oxygen species in lead-induced hypertension. Kidney Int 56:1492-1498.
44. Vupputuri S, He J, Muntner P, Bazzano LA, Whelton PK, Batuman V. 2003. Blood lead level is associated with elevated blood pressure in blacks. Hypertension 41:463-468.
45. Wetmur JG, Kaya AH, Plewinska M, Desnick RJ. 1991. Molecular characterization of the human delta-aminolevulinate dehydratase 2 (ALAD2) allele: implications for molecular screening of individuals for genetic susceptibility to lead poisoning. Am J Hum Genet 49:757-763.